SCHEMBL6018959

SCHEMBL6018959

Nc1ccc2c(c1)cc(C(=O)c1ccccc1N)n2CC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 4/20 0.46
MAPT P10636 2/20 0.41
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
FDPS P14324 1/20 0.39
GPR35 Q9HC97 2/20 0.39
APEX1 P27695 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
PKM P14618 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
MCL1 Q07820 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 1/20 0.37
F10 P00742 3/20 0.37
F2 P00734 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018665 0.84 CCR2 (0.47) CCR2MAPTPOLBTDP1
SCHEMBL6019178 0.79 ECE1 (0.55)
SCHEMBL6018965 0.78 KDM1A (0.50) CCR2MEN1KMT2A
SCHEMBL3844342 0.75 L3MBTL1 (0.71) CCR2L3MBTL1APEX1KMT2AKDM4E
SCHEMBL6467408 0.74 MAPT (0.37) CCR2MAPTGAAAPEX1MEN1
SCHEMBL1251025 0.73 CCR2 (0.47) CCR2MAPTGAAL3MBTL1APEX1
SCHEMBL15712747 0.72 CCR2 (0.74) CCR2GPR35F10
SCHEMBL7463101 0.69 CCR2 (0.71) CCR2L3MBTL1FDPSGPR35APEX1
SCHEMBL4409150 0.68 MAPT (0.59) MAPTGAAAPEX1MEN1USP2
Naphthylamine SCHEMBL28916448 0.68 ALDH1A1 (0.59) MAPTGAAL3MBTL1APEX1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183753-A1 Use of substituted 2,5-diamidoindoles for the treatment of urological diseases BAYER HEALTHCARE AG (DE) 2006-08-17 US disclosed
US-7045544-B2 Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases BAYER HEALTHCARE AG (DE) 2006-05-16 US disclosed
US-20050038101-A1 Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases BAYER HEALTHCARE AG (DE) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183753-A1 Use of substituted 2,5-diamidoindoles for the treatment of urological diseases DCK, UROD, QDPR CCR2 3450/4885MAPT 2350/4885GAA 1975/4885
US-20050038101-A1 Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases ECE1, ECE2, EDNRA CCR2 2595/4885MAPT 3259/4885GAA 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.